Roche leukaemia drug gets FDA breakthrough therapy designation

ZURICH (Reuters) - Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia (AML) from the U.S. Food and Drug Administration, the Swiss drugmaker said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news